CeraVe is facing 6 federal class action lawsuits over benzene forming in its acne products
CeraVe, owned by L'Oréal and widely identified as the most recommended skincare brand in America by dermatologists, is facing six federal class action lawsuits over claims that two of its acne products contain a confirmed human carcinogen. The products named across the complaints are the CeraVe Acne Foaming Cream Cleanser and the CeraVe Acne Foaming Cream Wash.
The lawsuits do not allege that CeraVe intentionally added a dangerous chemical. They allege that CeraVe failed to warn consumers that the active ingredient in those products, benzoyl peroxide, degrades into benzene under common storage and use conditions, and that CeraVe sold the products without disclosing that risk. The first lawsuit was filed in March 2024. By May 2025, all six had been consolidated to the Southern District of New York. As of June 2026, no final ruling has been issued and the litigation remains ongoing.
The ingredient is not the problem. What it becomes is.
Benzoyl peroxide is one of the most widely used acne treatments in the world. It works by releasing oxygen into the pore, killing the bacteria that cause acne. It is FDA-approved, over-the-counter, and present in dozens of products that sit in bathroom cabinets across the country.
It is also chemically unstable. Under heat, benzoyl peroxide degrades, and one of its breakdown products is benzene.
Benzene is not a borderline concern. The International Agency for Research on Cancer classifies benzene as a confirmed Group 1 human carcinogen, the same classification as asbestos and tobacco smoke. It is causally linked to acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. There is no established safe level of benzene exposure. A 2022 meta-analysis of human studies confirmed the association between benzene exposure and non-Hodgkin lymphoma across multiple independent cohorts (PMID: 35590014).
The degradation happens at temperatures people encounter every day
The issue was identified and formally brought to the FDA's attention by Valisure, an independent testing laboratory, in a Citizen Petition submitted on March 5, 2024. Valisure tested 111 benzoyl peroxide products and found that 34% contained benzene above the FDA's conditional limit of 2 parts per million. Concentrations in some products reached 35.30 ppm.
The temperature threshold for degradation is not extreme. Valisure's testing showed that at 37°C, equivalent to human body temperature, benzoyl peroxide products began generating dozens of parts per million of benzene within weeks. At 50°C, the level reached hundreds of ppm. At 70°C, the temperature inside a car on a hot summer day, one product released benzene at concentrations approximately 1,270 times higher than the EPA's threshold for increased cancer risk via long-term inhalation.
Your bathroom after a shower. A shipping warehouse. A car in the summer. These are not unusual conditions. They are the conditions under which these products are routinely stored, transported, and used.
The FDA tested 95 products and found most were fine at normal storage conditions
In March 2025, the FDA announced the results of its own testing of 95 benzoyl peroxide acne products. More than 90% had undetectable or extremely low levels of benzene. Six products had elevated levels, and seven products were subsequently voluntarily recalled, including La Roche-Posay Effaclar Duo, Proactiv Emergency Blemish Relief Cream, and Walgreens Acne Control Cleanser.
CeraVe's Acne Foaming Cream Cleanser and Acne Foaming Cream Wash were not among the products recalled. The FDA stated its position plainly: "Even with daily use of these products for decades, the risk of a person developing cancer because of exposure to benzene found in these products is very low."
That framing deserves scrutiny. The FDA's testing was conducted under standard storage conditions. Valisure's concern, and the basis of the lawsuits, is not what happens at standard conditions. It is what happens at elevated temperatures that are common in the real world, and whether consumers were told about that risk before purchasing the product.
The lawsuits are about disclosure, not just chemistry
The central claim across the six complaints is not that CeraVe's products will certainly cause cancer. It is that CeraVe knew or should have known that benzoyl peroxide is capable of generating benzene under foreseeable conditions, and chose not to put that information on the label or in any consumer communication.
That is a meaningful distinction. The ingredient list says benzoyl peroxide. Nothing says benzene. Nothing says store below a certain temperature. Nothing says the product becomes chemically different in a warm car or a steamy bathroom. Consumers buying a product marketed for daily facial use from the most dermatologist-recommended skincare brand in the country had no basis to ask that question.
The precedent matters beyond CeraVe. Benzoyl peroxide is present in hundreds of products from dozens of brands. If the lawsuits establish that manufacturers have a disclosure obligation when an active ingredient is capable of generating a carcinogen under common conditions, the standard for how these products are labeled and sold would change across the entire category.
What to do now
The FDA has not recalled CeraVe's specific acne products. The lawsuits are unresolved. If you currently use any benzoyl peroxide product, the most defensible guidance based on available evidence is to store it in a cool, temperature-stable environment rather than a bathroom cabinet or car, and to avoid leaving it in conditions where sustained heat exposure is likely.
If you are looking to transition away from benzoyl peroxide acne treatments while this situation develops, alternatives such as salicylic acid, azelaic acid, and niacinamide do not carry the same benzene degradation concern. The question of what is in your product when it reaches you is separate from the question of what it becomes between the shelf and your skin.